Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
Jonas Salk "I had an opportunity to spend time in elective periods in my last year in medical school, in a laboratory that was involved in studies on influenza. The influenza virus had just been discovered about a few years before that. And, I saw the opportunity at that time to test the question as to whether we could destroy the virus infectivity and still immunize. And so, by carefully designed experiments, we found it was possible to do so." In 1941, during his postgraduate work in virology, Salk chose a two-month elective to work in the laboratory of Thomas Francis at